MGO One Seven LLC Has $1.86 Million Stake in Zoetis Inc. (NYSE:ZTS)

MGO One Seven LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 64.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 11,401 shares of the company's stock after purchasing an additional 4,469 shares during the period. MGO One Seven LLC's holdings in Zoetis were worth $1,858,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its holdings in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the period. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the fourth quarter worth approximately $44,000. Asset Planning Inc acquired a new position in Zoetis in the fourth quarter valued at $58,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Zoetis during the 4th quarter worth approximately $59,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS traded down $0.03 during trading on Wednesday, reaching $155.40. The stock had a trading volume of 699,834 shares, compared to its average volume of 2,480,861. The stock has a 50 day moving average of $158.81 and a two-hundred day moving average of $167.98. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $69.34 billion, a price-to-earnings ratio of 28.41, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.29%. Zoetis's payout ratio is presently 36.56%.

Insider Buying and Selling at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of "Buy" and a consensus target price of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.